First-line (1L) osimertinib plus platinum-pemetrexed in EGFRmutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results

被引：0

作者：

Planchard, D. ^{[1
]}

Poltoratskiy, A. ^{[2
]}

Kim, S-W. ^{[3
]}

Kim, T. M. ^{[4
]}

Yanagitani, N. ^{[5
]}

Kagamu, H. ^{[6
]}

Feng, P-H. ^{[7
]}

Hughes, B. ^{[8
]}

Yang, T-Y. ^{[9
]}

Yang, J. C-H. ^{[10
,11
]}

Lee, C. K. ^{[12
]}

Karaseva, N. ^{[13
]}

Mitchell, P. ^{[14
]}

Tambo, Y. ^{[15
]}

Monterroso, E. Armenteros ^{[16
]}

Todd, A. ^{[17
]}

Sahasrabudhe, A. ^{[18
]}

Janne, P. A. ^{[19
]}

Kobayashi, K. ^{[20
]}

机构：

[1] Inst Gustave Roussy, Dept Med Oncol, Thorac Unit, Villejuif, France

[2] Petrov Res Inst Oncol, Dept Preclin & Clin Trials, St Petersburg, Russia

[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea

[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan

[6] Saitama Med Univ, Dept Gen Surg, Saitama, Japan

[7] Taipei Med Univ, Shuang Ho Hosp, Div Pulm Med, Dept Internal Med, Taipei, Taiwan

[8] Prince Charles Hosp, Dept Canc Care Serv, Herston, Qld, Australia

[9] Taichung Vet Gen Hosp, Dept Pulm Med, Taichung, Taiwan

[10] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[11] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[12] St George Hosp, Dept Med Oncol, Canc Care Ctr, Kogarah, NSW, Australia

[13] City Clin Oncol Hosp, Thorac Dept, St Petersburg, Russia

[14] Austin Hlth, Olivia Newton John Canc Ctr, Dept Oncol, Melbourne, Vic, Australia

[15] Kanazawa Univ Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan

[16] AstraZeneca, Late Dev Oncol R&D, Cambridge, England

[17] AstraZeneca, Oncol Biometr, Cambridge, England

[18] AstraZeneca, Dept Patient Safety Oncol, Cambridge, England

[19] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Dept Med Oncol, Boston, MA 02115 USA

[20] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Hidaka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.646

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

568P

引用

页码：S1692 / S1693

页数：2

共 50 条

[1] First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Cheng, Y.
Yu, Y.
Fan, Y.
Jiang, L.
Wu, L.
Hu, J.
Wang, J.
Yao, W.
Han, Z.
Yao, Y.
Fang, J.
Sun, M.
Wang, Q.
Pan, Y.
Wu, R.
Liu, J.
Liu, Y.
Kulkarni, D.
Huang, X.
Janne, P. A.
ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1689
[2] Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
Kim, S-W.
Planchard, D.
Feng, P-H.
Karaseva, N.
Kim, T. M.
Lee, C. K.
Poltoratskiy, A.
Yanagitani, N.
Powar, S.
Huang, X.
Howarth, P.
Janne, P.
Kobayashi, K.
ANNALS OF ONCOLOGY, 2020, 31 : S1382 - S1382
[3] Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
Planchard, D.
Feng, P-H.
Karaseva, N.
Kim, S-W.
Kim, T. M.
Lee, C. K.
Poltoratskiy, A.
Yanagitani, N.
Powar, S.
Huang, X.
Howarth, P.
Janne, P.
Kobayashi, K.
ANNALS OF ONCOLOGY, 2020, 31 : S888 - S888
[4] FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Planchard, D.
Janne, P. A.
Cheng, Y.
Lee, C. K.
Laktionov, K.
Yang, T-Y.
Yu, Y.
Kato, T.
Jiang, L.
Chewaskulyong, B.
Geater, S. Lucien
Maurel, J-M.
Rojas, C.
Havel, L.
Shepherd, F. A.
Tanaka, K.
Ghiorghiu, D.
Monterroso, E. Armenteros
Huang, X.
Yang, J. C-H.
ANNALS OF ONCOLOGY, 2023, 34 : S1668 - S1668
[5] FLAURA2: exploratory analysis of baseline (BL) and on-treatment plasma EGFRm dynamics in patients (pts) with EGFRm advanced NSCLC treated with first-line (1L) osimertinib (osi) ± platinum-pemetrexed
Janne, Pasi A.
Kobayashi, Kunihiko
Robichaux, Jacqulyne
Lee, Chee Khoon
Sugawara, Shunichi
Yang, Tsung-Ying
Kim, Tae Min
Yanagitani, Noriko
Kim, Sang-We
Markovets, Aleksandra
Bhetariya, Preetida
Poole, Lynne
Ghiorghiu, Dana
Hartmaier, Ryan
Yang, James Chih-Hsin
Planchard, David
CANCER RESEARCH, 2024, 84 (07)
[6] FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Planchard, D.
Janne, P. A.
Cheng, Y.
Lee, C. K.
Laktionov, K.
Yang, T. Y.
Yu, Y.
Kato, T.
Jiang, L.
Chewaskulyong, B.
Geater, S. Lucien
Maurel, J. M.
Rojas, C.
Havel, L.
Shepherd, F. A.
Tanaka, K.
Ghiorghiu, D.
Monterroso, E. Armenteros
Huang, X.
Yang, J. C. H.
ANNALS OF ONCOLOGY, 2023, 34 : S1311 - S1312
[7] First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort
Yang, J. C-H.
Kobayashi, K.
Chewaskulyong, B.
Tran, T. V.
Biswas, B.
Lee, K. H.
Feng, P-H.
Pham, X. D.
Yao, Y.
Kuyama, S.
Bing, J. Y. Tan Chun
Bhise, R.
Ahn, M-J.
Sriuranpong, V.
Li, R. K.
Monterroso, E. Armenteros
Barrett, K.
Albayaty, M.
Cheng, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S1635 - S1636
[8] Osimertinib With/Without Platinum-Based Chemotherapy as First-Line Treatment in Patients With EGFRm Advanced NSCLC (FLAURA2)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (10) : 3 - 4
[9] Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
Janne, P.
Planchard, D.
Cheng, Y.
Yang, J. C. -H.
Yanagitani, N.
Kim, S. -W.
Sugawara, S.
Yu, Y.
Fan, Y.
Geater, S. L.
Laktionov, K.
Lee, C. K.
Valdivieso, N.
Ahmed, S.
Maurel, J. -M.
Andrasina, I.
Goldman, J.
Ghiorghiu, D.
Kulkarni, D.
Huang, X.
Kobayashi, K.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S36 - S37
[10] FLAURA2: Impact of Tumor Burden on Outcomes of 1L Osimertinib ± Chemotherapy in Patients with EGFRmutated Advanced NSCLC
Valdiviezo, N.
Gray, J. E.
Janne, P. A.
Kobayashi, K.
Yang, J. C. -H.
Cheng, Y.
Lee, C. K.
Sugawara, S.
Yu, Y.
Kim, T. M.
Taggart, S.
Albayaty, M.
Ghiorghui, D.
Planchard, D.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S102 - S102

← 1 2 3 4 5 →